Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valbenazine for Chorea in Huntington Disease
NCT04102579Phase 3Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Nov 2019
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of valbenazine in Huntington disease (HD), sponsored by Neurocrine Biosciences. Started Nov 2019; status: completed.
02
Drugs
valbenazine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT04102579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04102579.